Clinical Trial Update: MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MBM-02 (Tempol) in biochemical recurrent prostate cancer is in progress, with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• MBM-02 (Tempol) (Tempol)

Snippet

Sponsor: Matrix Biomed, Inc. | Conditions: Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer | Phase 2 | Status: UNKNOWN